CSBio CSBio

X
[{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$1,250.0 million","upfrontCash":"$400.0 million","newsHeadline":"Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"JAPAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Kyowa Kirin"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kyowa Kirin and Amgen Present Positive Late-Breaking Data from Phase 2 Study of KHK4083\/AMG 451 in Adult Patients with Moderate-to-Severe Atopic Dermatitis at EADV Congress","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"JAPAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Kyowa Kirin"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Announces Positive Results in Phase 2b Study of Investigational TAK-279, an Oral, Once-Daily TYK2 Inhibitor, in People with Moderate-to-Severe Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Takeda Pharmaceutical"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            TAK-279 (NDI-034858) is a late-stage, highly selective, oral allosteric tyrosine kinase 2 (TYK2) inhibitor being evaluated for the treatment of multiple autoimmune diseases.

            Lead Product(s): NDI-034858

            Therapeutic Area: Dermatology Product Name: NDI-034858

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 18, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            KHK4083/AMG 451 is a potential first-in-class anti-OX40 fully human monoclonal antibody in development for the treatment of moderate-to-severe atopic dermatitis.

            Lead Product(s): AMG 451

            Therapeutic Area: Dermatology Product Name: KHK4083

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Amgen Inc

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 02, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            KHK4083 is an anti-OX40 fully human monoclonal antibody discovered by Kyowa Kirin and engineered with Kyowa Kirin’s patented POTELLIGENT® defucosylation technology to enhance its antibody-dependent cellular cytotoxicity (ADCC) activity.

            Lead Product(s): KHK4083

            Therapeutic Area: Dermatology Product Name: KHK4083

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Amgen Inc

            Deal Size: $1,250.0 million Upfront Cash: $400.0 million

            Deal Type: Collaboration June 01, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY